RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Clinical trials for RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibody combo shows promise for tough blood cancers
Disease control OngoingThis study tests an experimental drug called epcoritamab, given alone or with other medicines, in about 195 people whose chronic lymphocytic leukemia (CLL) or Richter's syndrome has stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink o…
Matched conditions: RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated May 17, 2026 06:47 UTC
-
New 'Four-in-One' antibody takes on Hard-to-Treat blood cancers
Disease control OngoingThis early-phase study tests a new drug called GNC-035, a special antibody that targets cancer cells in four ways. It is for people with chronic lymphocytic leukemia (CLL) or other blood cancers that have come back or stopped responding to treatment. The main goals are to check t…
Matched conditions: RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 14, 2026 12:06 UTC